TB Clinical Research: Training the Next Generation

结核病临床研究：培训下一代

• 批准号: 6908217
• 负责人: Carol D Hamilton
• 金额: $ 6.78万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6908217
• 关键词: bioinformatics; clinical research; clinical trials; combination chemotherapy; drug administration rate /duration; drug screening /evaluation; epidemiology; genetic susceptibility; genotype; health care personnel; human genetic material tag; human subject; human therapy evaluation; isoniazid; latent bacterial disease; patient care management; patient oriented research; public health; respiratory disease /disorder therapy; respiratory disorder diagnosis; rifamycins; single nucleotide polymorphism; statistics /biometry; training; tuberculin test; tuberculosis

DESCRIPTION (provided by applicant): The Investigator, Carol Dukes Hamilton, M.D., will use NIH K24 funding to help train future generations of clinical-scientists for a career in tuberculosis (TB) research. TB is responsible for more human deaths than any other infectious disease. Dr. Hamilton's long-term research goals are to optimize strategies for treating active and latent TB in adults and children. Strengths of her program include ongoing funding and active participation in the CDC-funded TB Trials Consortium clinical trials group, the CDC-funded TB Epidemiologic Studies Consortium, and an NHLBI-funded study of genetics of TB susceptibility. These funded programs form the basis of her research enterprise. They combine perfectly with the opportunities afforded by her position as the Medical Director for North Carolina's TB Control Program, providing an avenue for subject recruitment, clinical and epidemiologic research training for advisees, and the opportunity to implement changes based on the findings. The strength of Dr. Hamilton's TB research program is that she employs both clinical trials and epidemiologic studies to attain her research goals. Trainees can tap into one or the other methodologies during their training. Didactic course work leading to either a Masters in Clinical Research Science or Public Health is an integral part of Dr. Hamilton's mentoring plan. Dr. Hamilton will also strengthen her experiencebased research capability using these resources. Dr. Hamilton's research plan includes a description of the TB Trials Consortium clinical trial, "Study 26", comparing the effectiveness of 9 months of daily isoniazid therapy to 12 doses of weekly isoniazid plus rifapentine, for treatment of latent TB infection. Planned and potential sub-studies and secondary analyses provide fertile substrate for trainee-initiated research projects. The research plan also includes her NHLBI funded genetic epidemiologic study of candidate genes that may contribute to human TB susceptibility. Her work with the Duke Center for Human Genetics is an example of translational research she hopes to foster within her mycobacteria research program.

描述（由申请人提供）：调查员Carol Dukes Hamilton，M.D。将使用NIH K24资金来帮助培训子孙后代的临床科学家从事结核病（TB）研究。与任何其他传染病相比，结核病负责人类死亡更多。汉密尔顿博士的长期研究目标是优化针对成人和儿童的主动和潜在结核病的策略。她计划的优势包括持续的资金和积极参与CDC资助的结核病联盟临床试验组，CDC资助的TB流行病学研究联盟以及NHLBI资助的TB易感性遗传学研究。这些资助的计划构成了她的研究企业的基础。他们完美地结合了她作为北卡罗来纳州结核病控制计划医学总监的职位所带来的机会，为咨询服务提供了招聘，临床和流行病学研究培训的途径，以及根据发现的机会实施变化的机会。 汉密尔顿博士的结核病研究计划的优势在于，她使用临床试验和流行病学研究来实现她的研究目标。学员在培训期间可以利用一种或其他方法。导致临床研究科学硕士或公共卫生硕士的教学课程工作是汉密尔顿博士指导计划不可或缺的一部分。汉密尔顿博士还将使用这些资源来增强她基于经验的研究能力。汉密尔顿博士的研究计划包括对结核病联盟临床试验的描述，“研究26”，将9个月每天的异烟肼治疗的有效性与每周的每周Isoniaiazid Plus Rifapentine的12剂治疗潜在TB感染的有效性。计划和潜在的子研究和二级分析为学员发起的研究项目提供了肥沃的底物。该研究计划还包括她的NHLBI资助的候选基因遗传流行病学研究，这些研究可能有助于人类结核病的易感性。她在杜克大学人类遗传学中心的工作是她希望在分枝杆菌研究计划中培养转化研究的一个例子。